A
16.42
-0.52 (-3.07%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | ArriVent BioPharma, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.38 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 9.72% |
| 机构持股比例 | 84.55% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (Guggenheim, 174.06%) | 购买 |
| 中 | 39.00 (137.52%) | |
| 低 | 37.00 (B. Riley Securities, 125.34%) | 购买 |
| 平均值 | 40.33 (145.62%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 21.05 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| B. Riley Securities | 20 Mar 2025 | 37.00 (125.33%) | 购买 | 19.54 |
| Guggenheim | 10 Mar 2025 | 45.00 (174.06%) | 购买 | 21.73 |
| HC Wainwright & Co. | 07 Mar 2025 | 39.00 (137.52%) | 购买 | 21.87 |
| 22 Jan 2025 | 39.00 (137.52%) | 购买 | 26.63 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合